<DOC>
	<DOC>NCT00354367</DOC>
	<brief_summary>To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.</brief_summary>
	<brief_title>Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients with single or multiple fistulas, including perianal and enterocutaneous fistulas for at least 3 months as a complication of Crohn's disease Symptomatic obstructive intestinal strictures, bowel resection, proctocolectomy or total colectomy, abscesses present at screening, current total parenteral nutrition, short bowel syndrome. All the concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient. Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Crohn Disease</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Fistula</keyword>
</DOC>